PRMT5 and adrenal cortex carcinoma: While a small number of PRMT5 inhibitors have reached phase-I clinical trials in patients with advanced malignancies [18, 26, 41, 42, 45], responses have been suboptimal [40, 45], and the preclinical studies investigating the efficacy of PRMT5 blockade in ACC are still lacking, in part due to the scarcity of experimental model systems.